Which modality, small molecules or biologics, leads among the top-selling products? A look at the top-selling products industry-wide and blockbusters from select leading bio/pharma companies provides the answer. For the text version of this article visit dcatvci.org.

Key topics: (see Chapter Markers)

• Modality of top-selling products
• New drug approvals: small molecules versus biologics
• Potential blockbusters: small molecules and biologics
• Biogen’s and Eisai’s aducanumab
• Argenx’s efgartigimod
• Bristol-Myers Squibb’s mavacamten
• UCB’s bimekizumab
• Bristol Myers Squibb’s/bluebird bio’s idecabtagene vicleucel (ide-cel)
• Ascendis Pharma’s TransCon hGH (lonapegsomatropin)

Sponsor: LGM Pharma